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all the way from prototype design and preclinical studies to clinical trials and marketed products. The
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ABSTRACT
Diabetes mellitus is one of the major global health problems and the prevalence
rate is ever increasing reaching to 48% increase by the year of 2040 causing significant
economic burdens. Insulin therapy has been the mainstay of diabetes treatment since its
discovery in 1922. However, insulin is an unstable peptide with a half-life of only 4-6
min which poses significant challenge in prolonging duration of action of insulin.
Nevertheless, the advances in recombinant DNA technology and protein engineering
have enabled the development of several long-acting insulin analogue products which
show duration of action up to 42 h. However, these insulin analogues still require onceor twice-daily injections for optimal glycemic control resulting in poor compliance and
adherence issues among patients. To achieve insulin release for more than one day,
different injectable delivery systems including microspheres, in situ forming depots,
nanoparticles and composite systems have been developed for sustained release of insulin
for days to weeks in in vitro and preclinical studies. Several of these delivery systems
have further advanced to clinical trials for once-weekly insulin injection to treat diabetes.
Although a number of review articles have appeared in the literature to discuss the
developments of long-acting insulin analogues and sustained release insulin delivery
systems, none of them comprehensively cover the whole area starting all the way from
prototype design and preclinical studies to clinical trials and marketed products. The
scope of this review is to fill in the gap and comprehensively summarize the
developments of injectable insulin analogues and delivery systems for long-term
glycemic control and improved patient compliance.
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CHAPTER 1.

INTRODUCTION

Diabetes mellitus, commonly known as diabetes, is an endocrine disorder
characterized by persistently high blood glucose level over a prolonged period.
According to CDC National Diabetes Statistics Report published in 2017, nearly 30.3
million Americans, i.e. approximately 1 out of 10 people in US, have diabetes, and
among which about 5% of the patients have type 1 diabetes and 95% of the patients are
estimated to have type 2 diabetes [1]. The global economic burden of diabetes was
estimated $1.3 trillion in 2015 [2]. In US, the total cost of diagnosed diabetes was
estimated $327 billion in 2017 including $237 billion for direct medical costs and the rest
for reduced productivity of the diabetic patients [2]. Type 1 diabetes is characterized by
pancreatic β-cell destruction leading to absolute insulin deficiency; whereas type 2
diabetes is characterized by insulin resistance with a progressive deficiency in insulin
secretion by pancreatic β-cells, and [3]. Both type 1 and type 2 diabetes manifest
persistent elevation of blood glucose level including blood glucose concentration >125
mg/dL and hemoglobin A1c (HbA1c) level, a form of hemoglobin that is covalently
bound to glucose, >6.5% [4]. HbA1c is considered as a well-established surrogate for
long-term glycemic control and therefore, reductions in HbA1c reflects long-term
glycemic control. However, if untreated, both type of diabetes can cause serious
complications including stroke, myocardial infarction, vision loss, amputation, chronic
kidney diseases and mortality [5-7]. For patients with type 1 diabetes, multiple daily
injections of insulin are the only treatment option. For patients with type 2 diabetes, the
treatment starts with management of diabetes through change in life style including
healthy eating, weight loss and regular exercise followed by pharmacological
intervention with oral metformin monotherapy. If normoglycemia is still not achieved,
metformin is given in combination with the following small molecule oral medications:
sulfonylurea, thiazolidinedione, DPP-4 inhibitor and SGLT2 inhibitor [8]. However,
these oral medications often fail to achieve desired glucose lowering effect, and insulin
therapy is eventually included in the treatment regimen when the hemoglobin A1c
(HbA1c) level of type 2 diabetic patients is more than 6.5% [9]. Given the prevalence of
type 2 diabetes, type 2 diabetic patients account for the use of majority of insulin in the
market.
Insulin is an anabolic hormone with a short half-life of 4-6 min and it is secreted
from pancreatic beta cells. It regulates the blood glucose level in the body by facilitating
the absorption of glucose by different tissues such as liver, fat and muscle tissues. One
monomer of regular human insulin consists of an A chain and a B chain linked by two
disulfide bridges between two chains and one disulfide bond between two amino acids in
A chain. Two monomers form a dimer due to hydrogen bonding and hydrophobic
interactions [10, 11] and B chain residues B8, B9, B12, B16, B21 and B23-28 participate
in monomer-monomer interaction to form dimer (Figure 1-1) [12, 13]. Three dimers
form a hexamer in the presence of zinc where histidine residue at B10 position of each
monomer co-ordinates with zinc ion and A13, A14, A17, B1, B2, B4, B13, B14 and B1719 residues participate in dimer-dimer interaction (Figure 1-1) [12, 13]. Insulin remains
as hexamer in glucose regulated secretory vesicles of pancreatic beta cells. High blood
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Figure 1-1. Primary structure of native human insulin
The green indicates residues participating in monomer-monomer interaction leading to
dimerization, blue arrow indicates residue participating in dimer-dimer interaction to
form hexamer, black arrow indicates residue participating in co-ordination complex with
zinc ion and red indicates residues participating in insulin receptor binding.
Sources: Becker, R. H. (2007). Insulin glulisine complementing basal insulins: a review
of structure and activity. Diabetes technology & therapeutics, 9(1), 109-121. Brange, J.,
Owens, D. R., Kang, S., & Vølund, A. (1990). Monomeric insulins and their
experimental and clinical implications. Diabetes care, 13(9), 923-954.
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glucose concentration causes influx of a large amount of glucose inside the beta cells
through glucose transporter GLUT-2 which is preferentially expressed in the pancreatic
beta cell membrane [14]. This influx causes over production of cytosolic ATP which
promotes the closure of ATP sensitive potassium channels on the cell membrane [15]. As
a result, K+ ions are accumulated inside the cells causing depolarization of the plasma
membrane which in turn causes opening of the voltage-gated Ca2+ channels [15, 16]. As a
consequence, cytosolic Ca2+ concentration is raised and triggers exocytosis process by
which insulin containing secretory vesicles fuse with the plasma membrane and secrete
insulin hexamer [17].
The insulin hexamer is dissociated into monomer when secreted from the
pancreas [18, 19]. The insulin monomer is absorbed into the systemic circulation and
reaches adipose and muscle tissues where it binds with its receptor to exert its glucose
lowering effects on muscle and adipose tissues [20]. The amino acid residues A1, A5,
A19, A21, B10, B12, B16 and B23-25 participate in receptor binding of insulin [12]. In a
healthy person, insulin is continually secreted from the pancreas at a nearly constant rate
and maintain constant plasma insulin level after food absorption is ceased [21]. This is
called basal insulin secretion. After each meal, blood glucose level rises due to food
absorption and causes a surge in insulin secretion from the pancreas to facilitate glucose
utilization by the body which is called post-prandial insulin secretion [21].
Currently there are two types of insulin available in the market based on their
duration of action: rapid-acting or bolus insulins including insulin lispro, aspart and
glulisine which mimic the post-prandial insulin secretion and long-acting or basal
insulins including insulin glargine, detemir, and degludec which mimic the basal insulin
secretion from pancreas. Rapid-acting or bolus insulins are used after each meal to
control the post-prandial rise in blood glucose level whereas basal or long-acting insulins
are used to maintain stable blood glucose level during fasting state or between meals.
The rapid-acting insulins require multiple injections in a day and long-acting insulins
require once-daily injection for short-term glycemic control i.e. blood glucose
concentration < 125 mg/dL and long-term glycemic control i.e. HbA1c < 7%,
respectively. Repeated daily injections can cause serious patient non-compliance leading
to non-adherence to treatment and consequently, sub-optimal therapeutic outcomes [22].
To address these issues, substantial efforts have been made in the developments of
injectable sustained release systems that can release insulin for days to weeks to maintain
normoglycemia and eliminate the need of frequent dosing. Along with more conventional
sustained release systems including microspheres and in situ forming depots which have
been around for a few decades, several new technologies for sustained drug delivery
including nanoparticles, composite systems and glucose responsive systems have also
been investigated for sustained insulin release. Currently, a number of products have
advanced to clinical trials with the potential to transform the current once-daily basal
insulin therapy to once-weekly therapy. This thesis comprehensively reviews the current
trends and recent advancements in the development of injectable insulin analogs and
delivery systems from prototype design and preclinical studies to clinical trials and
marketed products as well as provides perspectives on future research and product
development in the field of long-lasting injectable insulin therapy.
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CHAPTER 2.

INJECTABLE INSULINS IN THE MARKET

Since its discovery in 1922, insulin has been mainstay treatment for patients with
diabetes mellitus. Insulin was first extracted from the pancreas of cows and pigs in 1921
by Frederick Banting and Charles Best. The extraction process was patented by Banting
and Best and later they decided to merge with Eli Lilly when the demand of insulin for
the treatment of diabetes surpassed their laboratory production limit [23]. Since then,
bovine and porcine insulins were life-saving medicine for diabetes patients, but the short
half-life (4-6 min) of insulin required frequent injection which was expensive as well as
caused medication non-adherence among patients. Therefore, extensive research efforts
were made to increase the duration of action of insulin between 1930-40. The first
breakthrough was made possible by Hans Christian Hagedorn at Nordisk Insulin
Laboratorium in 1936 [24]. He discovered that the action-time profile of injected insulin
could be prolonged by the addition of protamine. Protein molecules usually bear charges
because of the ionic nature of the amino acids. Therefore, different protein molecules are
soluble in different pH. The solubility of proteins is the least at its isoelectric point [25].
The addition of protamine in insulin increased its isoelectric point from 5.2 to close to
physiological pH resulted in the precipitation of insulin upon subcutaneous injection. As
a result, insulin was released slowly from the site of insulin precipitation. Further
experiments suggested that addition of zinc in insulin-protamine mixture formed insulin
crystals which further prolonged the insulin release from the injection site [26]. This
discovery led to the commercialization of insulin-protamine-zinc formulation in 1950 by
Nordisk which was called NPH (neutral protamine hagedorn) insulin. The NPH insulin
maintains its effect for 10-16 h but its absorption rate is unpredictable with high initial
burst and rapid fall from the peak concentration [27]. Therefore, NPH insulin is usually
mixed with regular insulin to achieve smoother action-time profile and better glycemic
control [28]. NPH insulin is the first long-acting insulin formulation introduced in the
market.
However, the insulins made from cows and pigs were reported to elicit allergic
reactions and immunological responses [29-32]. With the later advent of recombinant
DNA technology, biosynthetic human insulin was invented to replace bovine and porcine
insulins. Genentech was the first company to develop recombinant human insulin (RHI)
in 1978 which was approved by FDA in 1982 but they did not commercialize the product
by themselves. In 1983, Eli Lilly and Company marketed the product under the brand
name Humulin® after FDA approval and it is considered the first genetically engineered
biologic drug [24]. Later on, Eli Lilly also marketed their own recombinant NPH insulin
followed by Novo Nordisk’s recombinant human insulin and NPH. Recombinant human
insulin is structurally and functionally similar to regular human insulin produced by
natural pancreatic β cells and also has a short half-life of 4-6 min [33]. To increase the
half-life of the recombinant human insulin, change of the amino acid sequences in native
insulin and conjugation with long chain fatty acids to native insulin have been the central
strategies to design long-lasting insulin analog. In addition, excipients such as zinc, meta
cresol, glycerol and protamine sulfate have also been used extensively in insulin
formulation development because zinc promotes insulin hexamer formation [10, 11],
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meta cresol stabilizes insulin [34], glycerol is a tonicity adjuster [35], and protamine
sulfate can increase the isoelectric point of insulin from 5.2 to close to physiological pH
to form insulin precipitates after subcutaneous injection [26]. In this Chapter 2, I focus on
the review of two major types of human insulin analogs that have been available in the
market: rapid acting or mealtime, and long-acting or basal insulin analogs including their
analog designs, excipients in the formulations, and devices for delivering the analogs.
Table 2-1 provides an overview of currently available insulins and insulin analogs with
their action-time profile. [36]
Insulin Analogs
Rapid-Acting Insulin Analogs
Rapid-acting insulin analogs are a type of recombinant insulin that has rapid onset
of action with immediate pharmacodynamic effect. The products available in the market
that belong to this category are insulin lispro, aspart and glulisine, whose B chain’s amino
acid was modified to reduce zinc mediated hexamer formation which is observed in
regular insulin [6]. As a result, these insulin analogs are released into the bloodstream
rapidly after subcutaneous injection. In this way, these analogs mimic the prandial
insulin secretion of the body, the natural insulin secretion by pancreas after each meal,
and thus are prescribed by doctors to maintain the blood glucose level after meal.
Compared to regular human insulin and NPH insulin, insulin lispro, aspart and glulisine
have faster onset of action, higher peak concentration and shorter duration of action.
Below are the detailed discussions of the features and functions of insulin lispro, aspart
and glulisine.
Insulin lispro
The first-in-class rapid-acting insulin analog was insulin lispro which was
marketed in 1996 by Eli Lilly under a trade name of Humalog®. Insulin lispro was
developed by interchange between proline and lysine at 28 and 29 position in B chain of
regular insulin, respectively (Figure 2-1). The inversion of ProB28LysB29 resulted in
destabilization and rapid dissociation of formed hexamers into monomers and dimers
causing rapid absorption of insulin into the systemic circulation after subcutaneous
injection [37]. In 2017, Sanofi received FDA approval for Admelog® which is the first
short-acting “follow-on” product of insulin lispro. Admelog® has an amino acid sequence
identical to Humalog® and showed similar pharmaceokinetic and pharmacodynamic
profile in clinical trials [38].
Insulin aspart
The second addition in rapid-acting insulin analogs is insulin aspart which was
approved in 2000 and developed by Novo Nordisk under a trade name of Novolog®. In
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Table 2-1.
Type
Rapid-acting or
mealtime
insulin analogs

Currently approved insulin injectables available in the US market
Insulin/Insulin
Analogs
Lispro

Trade Name
Humalog®
Admelog®

Aspart

Novolog®
Fiasp®

Long-acting or
basal insulin
analogs

Gluisine

Apidra®

Regular human
insulin (RHI)

Humulin® R
(U-100)
Novolin® R

Neutral
protamine
Hagedorn
(NPH)

Glargine
(100 U/ml)

Manufacturer
(Approval Date)
Eli Lilly
(1996)
Sanofi
(2017)
Novo Nordisk
(2000)
Novo Nordisk
(2017)
Sanofi
(2004)
Eli Lilly
(1982)
Novo Nordisk
(1991)

Onset

Time of Action
Peak
Duration

15 min

30-90 min

3-5 h

15 min

30-90 min

3-5 h

15 min

30-90 min

3-5 h

2.5 min

30-60 min

3-5 h

15 min

30-90 min

3-5 h

30-60 min

2-3 h

21 h

30-60 min

2-3 h

10-16 h

<15 min

4-8 h

~ 24 h

2-4 h

4-10 h

10-16 h

Humulin® R
(U-500)
Humulin® N

Eli Lilly
(1994)
Eli Lilly
(1982)

Novolin® N

Novo Nordisk
(1991)

2-4 h

4-10 h

10-16 h

Lantus®

Sanofi
(2000)
Eli Lilly
(2015)
Novo Nordisk
(2005)
Sanofi
(2015)
Novo Nordisk
(2015)

2-4 h

No peak

~ 24 h

2-4 h

No peak

~ 24 h

3-4 h

No peak

20-24 h

6h

No peak

~ 32 h

3-4 h

No peak

~ 42 h

Basaglar®
Detemir

Levemir®

Glargine
(300 U/ml)
Degludec

Toujeo®
Tresiba®
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Dosing Time
3-5 min
before meal
3-5 min
before meal
0-15 min
before meal
0-15 min
before meal
0-15 min
before meal
30 min before
meal
Once at
bedtime or
twice daily
Once or twice
daily
Once at
bedtime or
twice daily
Once at
bedtime or
twice daily
Once or twice
daily
Once or twice
daily
Once or twice
daily
Once or twice
daily
Once daily

Route of
Administration
SC or IV
SC or IV
SC or IV
SC or IV
SC or IV
SC
SC
SC
SC

SC
SC
SC
SC
SC
SC

Table 2-1.
Type
Premixed
insulins

(Continued)
Insulin/Insulin
Analogs
70% neutral
protamine
hagedorn and
30% regular
human insulin

Trade Name
Humulin®
70/30

Manufacturer
(Approval Date)
Eli Lilly
(1989)

Novolin®
70/30
75% insulin
lispro protamine
and 25% lispro

Onset

Time of Action
Peak
Duration

Dosing Time

30-60 min

2-6 h

12-18 h

Twice daily
before
breakfast and
dinner

Novo Nordisk
(1991)

30-60 min

2-6 h

12-18 h

HumaLog®
Mix 75/25

Eli Lilly (1999)

5-15 min

2-4 h

14-24 h

50% insulin
lispro protamine
and 50% lispro

HumaLog®
Mix 50/50

Eli Lilly (1999)

5-15 min

2-4 h

14-24 h

70% insulin
aspart protamine
and 30% aspart

NovoLog®
Mix 70/30

Novo Nordisk
(2001)

5-15 min

2-4 h

14-24 h

70% insulin
degludec
protamine and
30% aspart

Ryzodeg®
70/30

Novo Nordisk
(2015)

15 min

30-90 min

>24 h

Twice daily
before
breakfast and
dinner
Twice daily
before
breakfast and
dinner
Twice daily
before
breakfast and
dinner
Twice daily
before
breakfast and
dinner
Once or twice
daily before
meal

Route of
Administration
SC

SC

SC

SC

SC

SC

Notes: SC=Subcutaneous, IV=Intravascular.
Sources: Pechenov, S., Bhattacharjee, H., Yin, D., Mittal, S., & Subramony, J. A. (2017). Improving drug-like properties of
insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery.
Advanced drug delivery reviews, 112, 106-122. Jayakrishnapillai, P. V., Nair, S. V., & Kamalasanan, K. (2017). Current trend
in drug delivery considerations for subcutaneous insulin depots to treat diabetes. Colloids and Surfaces B: Biointerfaces, 153,
123-131. Yu, J., Qian, C., Zhang, Y., Cui, Z., Zhu, Y., Shen, Q., Ligler, F.S., Buse, J.B. and Gu, Z. (2017). Hypoxia and H2O2
dual-sensitive vesicles for enhanced glucose-responsive insulin delivery. Nano letters, 17(2), 733-739. American Diabetes
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Table 2-1.

(Continued)

Association (2018). Lipska, K. J., Hirsch, I. B., & Riddle, M. C. (2017). Human insulin for type 2 diabetes: an effective, lessexpensive option. Jama, 318(1), 23-24. Mathieu, C., Gillard, P., & Benhalima, K. (2017). Insulin analogs in type 1 diabetes
mellitus: getting better all the time. Nature Reviews Endocrinology, 13(7), 385.
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Figure 2-1. Structural modifications of human insulin to develop insulin analogs
A: The amino acid modifications in rapid-acting insulin analogs decrease hexamer
formation and increase insulin solubility and absorption from subcutaneous space after
injection causing rapid action-time profile.
B: The amino acid modifications and fatty acid conjugation in long-acting insulin analogs
lead to formation of multihexamer structures in subcutaneous space after injection and
reversible albumin-binding in the circulation, respectively, causing prolonged duration of
action.
Reprinted from Advanced drug delivery reviews, 112, Pechenov, S., Bhattacharjee, H.,
Yin, D., Mittal, S. and Subramony, J.A., Improving drug-like properties of insulin and
GLP-1 via molecule design and formulation and improving diabetes management with
device & drug delivery, 106-122, 2017, with permission from Elsevier.
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insulin aspart, proline at B28 position of regular insulin was substituted with aspartic acid
(Figure 2-1). As a result, the insulin’s hexamer formation is inhibited, isoelectric point is
reduced and solubility at physiological pH is increased due to the negative charge of
aspartic acid, and thus insulin is rapidly available in the bloodstream upon subcutaneous
injection [39]. The pharmacokinetic-pharmacodynamic profile of insulin aspart is similar
to that of insulin lispro [40]. In 2017, Novo Nordisk received FDA approval for its
insulin aspart brand-named Fiasp® which has additional nicotinamide (vitamin B3) and
arginine as excipients in its formulation, to increase the initial absorption rate of insulin
[41]. Fiasp® acts faster than Novolog® with 2.5 vs. 15 min onset of appearance in the
bloodstream [6, 42].
Insulin glulisine
The most recent rapid-acting insulin analog is insulin glulisine which was
approved by FDA in 2004 and introduced to the market in 2006 by Sanofi under a trade
name Apidra®. In insulin glulisine, the asparagine at position B3 and lysine at position
B29 of regular insulin were replaced by lysine and glutamic acid, respectively to decrease
the isoelectric point and thus increase the solubility of the insulin (Figure 2-1) [12].
Insulin glulisine demonstrates slightly faster onset of action than insulin lispro and aspart
due to the absence of zinc in its formulation (zinc promotes hexamer formation causing
slow availability of functional insulin monomer) [12, 43].
Long-Acting Insulin Analogs
Long-acting insulin analogs are a type of recombinant human insulin that can
continuously provide exogenous basal insulin to maintain normoglycemia for up to 24 h
[22, 44, 45]. The products available in the market that belong to this category are insulin
glargine, detemir, and degludec. The design strategies for these long-acting insulin
analogs include modification of the amino acid sequence of insulin to facilitate hexamer
formation and conjugation of fatty acid to the insulin chain to increase the circulation
time of insulin (half-life) in the bloodstream via reversible binding with albumin [6].
Below are the detailed discussions of the features and functions of insulin glargine,
detemir, and degludec.
Insulin glargine (100 U/mL)
The first long acting insulin analog introduced in the market was Sanofi’s insulin
glargine which was approved by FDA in 2000 and marketed under a trade name Lantus®.
In insulin glargine 100 U/mL, asparagine at A20 position of regular insulin was replaced
with glycine and two arginine molecules were added to the B chain of regular insulin to
shift the isoelectric point of insulin close to physiological pH (Figure 2-1) [46]. As a
result, insulin glargine 100 U/mL is soluble in acidic pH in the vial but precipitates to
form zinc mediated hexamer aggregates leading to slow insulin release after
subcutaneous injection. Insulin glargine 100 U/mL demonstrated a flatter and longer
pharmacokinetic-pharmacodynamic profile than NPH insulin and can decrease the risk of
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nocturnal hypoglycemia in most patients in once daily-dosing [47, 48]. In 2015, FDA
approved the first “follow-on” product of insulin glargine developed by Eli Lilly and
Company and marketed as Basaglar®. Basaglar® and Lantus® are structurally identical
and have similar efficacy and safety profile [49].
Insulin detemir
Insulin detemir is the second long-acting insulin analog approved by FDA (2005)
and commercialized by Novo Nordisk under a trade name Levemir®. In detemir,
threonine was removed from the position B30 and myristoyl fatty acid (C14) was
conjugated to B29 lysine of regular insulin to promote di-hexamer formation of insulin
with zinc after subcutaneous injection (Figure 2-1). The di-hexamers are dissociated into
hexamers and then slowly into monomers to be absorbed in the systemic circulation. In
addition, the conjugated fatty acid facilitates reversible binding of insulin with albumin in
the systemic circulation to further prolong the action of detemir. In clinical trials, insulin
detemir showed better glycemic control than NPH insulin [48, 50]. Although same
glycemic control was achieved by insulin detemir in higher dose when compared with
insulin glargine 100 U/mL, insulin detemir causes less weight gain than insulin glargine
100 U/mL in clinical trials [51, 52].
Both insulin glargine 100 U/mL and insulin detemir have advantages over NPH
insulin because of their longer duration of action, lesser inter- and intra-individual
variabilities and fewer episodes of hypoglycemic events [33]. In comparison with insulin
glargine 100 U/mL, insulin detemir has even less pronounced inter- and intra-individual
variabilities [53]. Although insulin glargine 100 U/mL and detemir are reported to
provide glycemic control for 24 h, more frequent than once-daily regimen has been
observed to provide improved glycemic control in clinical practice [51, 54]. Considering
these issues, newer basal insulin analogs have been developed with a view to providing
better glycemic control with fewer injections by improving patient compliance [55]. At
present, there are two such basal insulin analogs available in the US market: insulin
glargine 300 U/mL and insulin degludec 100 U/mL and 300 U/mL. They are usually
prescribed as once-daily injection.
Insulin glargine (300 U/mL)
Insulin glargine injection 300 U/mL is a highly concentrated version of Lantus®
available in 300 U/mL. It was approved by FDA in 2015 and is currently marketed by
Sanofi under a trade name of Toujeo®. After subcutaneous injection, insulin glargine 300
U/mL precipitates at physiological pH to form concentrated insulin-zinc hexamer
aggregates which are more compact than aggregates formed by insulin glargine 100U/mL
(Figure 2-2). Therefore, insulin glargine 300 U/mL showed longer action than NPH and
insulin glargine 100 U/mL [56]. In clinical studies, insulin glargine 300 U/mL
demonstrated better steady-state pharmacokinetic-pharmacodynamic profile, better 24 h
coverage irrespective of the injection time with less increase in the glucose level in the
last 4 h, and reduced risk of nocturnal hypoglycemia than insulin glargine 100 U/mL [57,
58].
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Figure 2-2. Protraction mechanism of insulin analogs
The effect of self-aggregation nature of insulin and insulin analogs on their rate of
absorption and duration of action has been shown. Preventing hexamer formation by
amino acid modification in rapid acting analogs causes rapid dissociation of hexamer into
monomer and dimer resulted in fast absorption rate and short duration of action (lispro,
aspart and glulisine). Positively charged protamine stabilizes native insulin hexamer and
causes slower insulin release and longer duration of action (NPH insulin). Amino acid
modification and fatty acid conjugation in long acting insulin analogs cause formation of
dihexamer (detemir), hexamer aggregates (glargine) and multi-hexamer chains
(degludec) and slows down the absorption and prolongs duration of action. Fatty acid
conjugation further extends the half-life by binding with albumin in the circulation
(detemir and degludec).
Reprinted by permission from Nature Publishing Group: Springer Nature, Nature Review
Endocrinology, Insulin analogs in type 1 diabetes mellitus: getting better all the time,
Mathieu, C., Gillard, P., & Benhalima, K., 2017.
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Insulin degludec
Insulin degludec was developed by Novo Nordisk as a longer acting version of
their previous analog, insulin detemir. Insulin deguldec is available in 100 U/ml and 200
U/ml formulations and approved for once-daily dosing regimen. It was approved in 2015
and marketed under the trade name of Tresiba®. In degludec, Threonine at position B30
of regular insulin was removed and a C16 fatty acid was attached to the LysB29 via a
Glutamic acid spacer (Figure 2-1) [43]. In the presence of phenol and zinc, insulin
degludec forms dihexamer in the vial. Following subcutaneous injection, phenol is
diffused out resulting in the formation of multi-hexamer chains. Multihexamers are
gradually dissociated into dimers and monomers by the removal of zinc which provides
slow and continuous delivery of insulin degludec into the circulation for a prolonged time
(Figure 2-3). The protraction is further achieved by reversible binding of degludec with
circulating albumin [59, 60] (Figure 2-2). In clinical trials, insulin glargine demonstrated
a flat and stable glucose lowering effect [61], four-fold decrease in within-subject
variability in glucose lowering effect [61] and reduction in nocturnal hypoglycemia when
compared with insulin glargine [62]. Till date, insulin degludec is the longest acting
insulin analog available in the market with a duration of action about 42 h with a flexible
dosing regimen. As a result, patients who are on once daily insulin degludec dosing
regimen, in case of missing dose, can take the dose with time intervals of minimum 8
hours to maximum 40 hours without compromising the glycemic control [63, 64]. On the
contrary, insulin glargine and detemir are required to be injected every day (often twicedaily) at the same time to maintain normoglycemia [64].
Premixed Insulins
Premixed insulins are developed by combining regular human insulin or rapid
acting analogs with its protamine complex to achieve better glycemic control and limit
the number of injections per day. Currently, there are six premixed insulins available in
the US market (Table 2-1). Regular insulin based premixed formulations (Novolin® 70/30
and Humulin® 70/30) are prepared by mixing 70% NPH insulin and 30% regular human
insulin. Premixed formulations prepared from insulin analogs (NovoLog® Mix 70/30,
Humalog® Mix 75/25 and Humalog® Mix 50/50) usually contain rapid acting analogs
mixed with its protamine complex in variable amount and they usually demonstrate
shorter onset and longer duration of action compared to regular premixed preparations. In
clinical trial, one injection of premixed insulin decreased HbA1c level significantly
(0.2%) compared to one injection of long-acting and one injection of short-acting insulin
[65]. Also, premixed insulin analogs have been found to provide better post-prandial
glycemic control compared to premixed human insulin, although longer-term glycemic
control was comparable for both [66]. Patients usually prefer premixed insulin because of
less number of injections, however, they are inconvenient for intensive insulin regimens
which may require full basal bolus regimen which is up to 4 injections per day [65]. In
this regard, Ryzodeg® 70/30, a premixed insulin with 70% insulin degludec and 30%
insulin aspart, showed successful glycemic control with fewer injections than a basalbolus regimen with significantly less weight gain and lower daily insulin dose (12%) in
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Figure 2-3. Protraction mechanism of insulin degludec
Insulin degludec remains as dimer in vial in the presence of zinc and phenol. Upon
subcutaneous injection, phenol is diffused out and multi-hexamer chains are formed.
Slow removal of zinc causes dissociation of multihexamer chains into monomer and
dimer for absorption.
Reprinted with open access permission. Jonassen, I., Havelund, S., Hoeg-Jensen, T.,
Steensgaard, D. B., Wahlund, P. O., & Ribel, U. (2012). Design of the novel protraction
mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharmaceutical
research, 29(8), 2104-2114.
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clinical trial [67].
Excipients in Long-Acting Insulin Analog Formulations
In order to promote hexamer formation and albumin binding to achieve longer
action-time profile, the amino acid modification and fatty acid conjugation are usually
done in B26-30 of insulin residues which preserves its biological activity [68, 69].
Various excipients are also added to the insulin formulations to stabilize the hexamer
(Table 2-2). Thus, excipients, along with structure modifications, also play a key role in
formulation development of long acting insulin products.
However, insulin undergoes fibrillation when exposed to elevated temperature,
agitation, low pH, organic solvents and increased ionic strength [70, 71]. Insulin
fibrillation is a limiting factor in long term storage of marketed insulin preparations and
predominantly occurs when insulin remains in its monomeric state [72]. Upon long term
storage, conformational distortion of the monomers leads to partially folded intermediate
and this partial fold may unfold completely or form amyloidogenic nuclei which
ultimately leads to the formation of insulin fibril/filament (Figure 2-4) [73]. To
overcome this problem, insulin needs to remain in its hexameric form in the marketed
preparations and addition of zinc and phenolic compounds such as phenol and meta
cresol to the insulin formulations facilitates this hexamer formation by exploiting the selfassociation nature of insulin monomers [72, 74]. Therefore, all long acting insulin
formulations available in the market contain zinc, glycerol and phenol or meta cresol or
both. As mentioned earlier, addition of zinc promotes hexamer formation while glycerol
is used to adjust the tonicity of the formulation. Phenol and meta cresol are primarily
used as preservative as well as hexamer stabilizer in the formulation. However, NPH
insulin formulation contains protamine sulfate which, as previously discussed, is used to
increase the isoelectric point from 5.2 to close to physiological pH and therefore, insulin
is precipitated and forms depot after subcutaneous injection [26]. Addition of phenolic
compounds is especially important for degludec and detemir formulations because high
concentration of phenolic compounds directs insulin-zinc hexamer to adopt a specific
conformation that only allows di-hexamer formation of these analogs in the vial [75, 76].
This process is also driven by anions such as chloride ion and therefore, sodium chloride
is also added to detemir and degludec formulation [76]. Besides, Lantus® (insulin
glargine) formulation contains polysorbate 20, a surfactant, which is used to prevent
turbidity in the formulation [77]. Sodium hydroxide or hydrochloric acid is used to adjust
the formulation pH while dibasic sodium phosphate is used as a buffering agent to
maintain the pH.
Devices for Delivering Insulin Analogs
Insulin is commonly administered through subcutaneous route due to the ease of
self-administration and it is usually delivered using different methods such as vial and
syringes, insulin pens, jet injectors and insulin pumps. The most common method of
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Table 2-2.
Insulin or
Insulin
Analogs
Neutral
protamine
Hagedorn
(NPH)
(5808 Da)

Excipients in long-acting insulin formulations
Trade
Name
Humulin®
N

Novolin®
N

Insulin
Glargine
(100
U/ml)
(6063 Da)

Lantus®

Basaglar®

Detemir
(5916.9
Da)

Levemir®

Glargine
(300
U/ml)
(6063 Da)

Toujeo®

Degludec
(6103.97
Da)

Tresiba®

Excipients
(per ml)
Human insulin recombinant: 100 U (Escherichia
coli), Protamine sulfate: 0.35 mg, Glycerol: 16 mg,
Dibasic sodium phosphate: 3.78 mg, Metacresol:
1.6 mg, Phenol: 0.65 mg, Zinc: 0.025 mg (ZnO),
Water for injection, Sodium hydroxide and/or
hydrochloric acid to adjust pH to 7-7.5
Human insulin: 100 U (Saccharomyces cerevisiae),
Protamine sulfate: 0.35 mg, Zinc: 0.0335 mg,
Metacresol: 1.6 mg, Phenol: 0.65 mg, Glycerol: 16
mg, Dibasic sodium phosphate dihydrate: 2.4 mg,
Water for injection, Sodium hydroxide (2N) and
hydrochloric acid (2N) to adjust pH to 7.1-7.5
Insulin glargine recombinant: 100 U ((Escherichia
coli), Zinc: 0.03 mg, Metacresol: 2.7 mg, Glycrol
(85%): 20 mg, Polysorbate 20: 0.02 mg, Water for
injection, Sodium hydroxide and/or hydrochloric
acid to adjust pH to ̴ 4
*3 ml prefilled pen does not contain polysorbate 20.
All other excipient amounts are same.
Insulin glargine recombinant: 100 U (Escherichia
coli), Zinc: 0.03 mg, Metacresol: 2.7 mg, Glycrol
(85%): 17 mg, Water for injection, Sodium
hydroxide and/or hydrochloric acid to adjust pH to ̴
4
Insulin detemir recombinant (followed by chemical
modification): 100 U (Saccharomyces cerevisiae),
Zinc: 0.0654 mg, Metacresol: 2.06 mg, Glycerol
(85%): 16 mg, Phenol: 1.8 mg, Disodium phosphate
dihydrate: 0.89 mg, Sodium chloride: 1.17 mg,
Water for injection, Sodium hydroxide and/or
hydrochloric acid to adjust pH to ̴ 7.4
Insulin glargine recombinant: 300 U (Escherichia
coli), Zinc: 0.090 mg, Metacresol: 2.7 mg, Glycerol
(85%): 20 mg, Water for injection
Sodium hydroxide and/or hydrochloric acid to
adjust pH to ̴ 4
Insulin degludec recombinant (followed by
chemical modification): 100 U (Saccharomyces
cerevisiae), Zinc: 0.0327 mg, Metacresol: 1.72 mg,
Glycerol: 19.6 mg, Phenol: 1.50 mg, Di sodium
phosphate dihydrate: 0.89 mg, Sodium chloride:
1.17 mg, Water for injection
Sodium hydroxide and/or hydrochloric acid to
adjust pH to ̴ 7.6
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Physical
Ref.
Appearance
White
suspension

[78]

White and
cloudy
suspension

[79]

Clear
aqueous
fluid

[80]

Colorless
aqueous
solution

[81]

Colorless
aqueous
solution

[82]

Clear
aqueous
fluid

[83]

Colorless
aqueous
solution

[84]

Figure 2-4. Mechanism of insulin fibrillation in monomeric form
Pathway of insulin fibril formation via partial unfolding of monomers leading to
amyloidogenic nuclei and insulin fibril/filament.
Reprinted with permission. Yang, Y., Petkova, A., Huang, K., Xu, B., Hua, Q.X., Ye, I.J.,
Chu, Y.C., Hu, S.Q., Phillips, N.B., Whittaker, J. and Ismail-Beigi, F. (2010). An
Achilles' Heel in an Amyloidogenic Protein and Its Repair INSULIN FIBRILLATION
AND THERAPEUTIC DESIGN. Journal of Biological Chemistry, 285(14), 1080610821.
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Insulin delivery is vial and syringes. Although it is the most cost-effective option, there
are several disadvantages in this method such as needle phobia of the patients, infection
and sickness associated with multiple use of needles, use of incorrect insulin product and
inaccurate dose administration [85]. Therefore, this method is becoming less popular
among patients and doctors. Insulin pens are gaining preference in this respect owing to
their advantage of dose accuracy, reusability and safety features. But they are associated
with higher cost in comparison with vials and syringes. In several studies, insulin pens
were found to be more accurate than syringes in measuring low insulin dose especially
less than 5 units as well as socially more acceptable [85-87]. However, insulin pens are
also associated with skin penetration, although to a lesser extent compared to vial and
syringe method. Therefore, jet injectors have been developed to deliver insulin without
skin penetration. Jet injector uses high pressure narrow jet of liquid insulin formulation
instead of needle to penetrate the skin. In diabetic patients, insulin jet injectors showed
increased insulin absorption and significant decrease in plasma glucose level compared to
insulin pens [88, 89]. Insulin delivered via jet injectors also showed PK profile more
close to endogenous insulin and significant improvement in post-prandial glucose control
compared to pens in diabetes patients [90]. However, physiologically relevant insulin
delivery requires to mimic the pattern of natural insulin secretion from pancreas. Insulin
pump therapy can serve this purpose by providing continuous supply of insulin at
variable rate in response to the alteration in blood glucose level. In clinical trials, insulin
pump therapy showed significant glucose lowering effect, long-term glycemic control
and reduction in insulin dose compared to conventional multiple daily injections [91, 92].
Yet, higher cost, inconvenience of constantly wearing it and training requirement limit
the broad use of insulin pump among diabetes patients.
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CHAPTER 3.

INJECTABLE DELIVERY SYSTEMS FOR INSULIN

The concept of using drug delivery systems to prolong the action-time profile of
insulin was first materialized by Parkes and Young in 1939 [93]. They implanted solid
tablets made of insulin powder in the subcutaneous space in rabbits but unfortunately, it
showed slight prolongation of duration of action of insulin compared to regular insulin
injection. This unsuccessful attempt led to the use of polyacrylamide slurry for sustained
delivery of insulin [94]. Subcutaneous injection of insulin loaded polyacrylamide slurry
maintained the growth of diabetic rats at a normal rate until the removal of the implant
after 21 days. However, polyacrylamide causes irritation in animal tissues due to its
inflammatory nature and therefore, non-inflammatory vinyl acetate-ethylene copolymer
was synthesized to develop sustained release implant of insulin [95]. Insulin loaded vinyl
acetate-ethylene copolymer disc was implanted subcutaneously in streptozotocin induced
diabetic rats. Insulin was released for 29 days in biologically active form and
consequently, maintained normoglycemia as well as normal weight gain. Vinyl-acetateethylene copolymer was non-inflammatory in nature but the need for surgical
implantation and removal of the implant was inconvenient. As a consequence,
biodegradable and injectable liposomal system was developed with egg lecithin which
resolved the issues related to surgical procedure and inflammation [96]. But the glucose
lowering effect was observed only for little more than 7 hours , although a small response
still remained 24 h after injection. To extend the release of insulin with biodegradable
systems, albumin microbeads were prepared which showed sustained release of insulin
for more than two weeks after subcutaneous implantation [97, 98]. Although albumin
microbeads demonstrated sustained insulin release and eliminated the need of surgical
removal of implant, the surgical implantation still remained an issue which was finally
resolved by the use of polylactic acid (PLA) based microcapsules [99, 100]. Insulin
loaded PLA microcapsules maintained normoglycemia for five days in diabetic rats. This
was the earliest example of a biodegradable injectable system for sustained delivery of
insulin. In the next few decades, the use of poly lactic acid and polyglycolic acid (PLGA)
based polymers gave rise to the development of numerous sustained release systems. As a
consequence, complex dosage forms such as microspheres, nanoparticles, in situ forming
depots, and composite systems have emerged as novel delivery technologies for sustained
release of insulin (Figure 3-1). This chapter will give a brief overview of each of the
systems along with their advantages and limitations.
Microspheres
Microspheres are spherical particles with a size range of 1-1000 μm and are
usually prepared from natural or synthetic polymers. In the last few decades, microsphere
based delivery systems have been extensively investigated for sustained release of protein
and peptide drugs [101, 102]. Microspheres have been shown to release drugs over a long
time spanning from days to months [102-104]. Starting in the late 90s, the concept of
using biodegradable polymers to develop sustained release microspheres for insulin was
pioneered by Lin et al. by emulsification-solvent evaporation method [99, 100]. The
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Figure 3-1. Summary findings and representative images of sustained release
delivery systems for insulin investigated in preclinical studies
A: SEM image of insulin loaded salicylic acid-poly(anhydride ester) microspheres. The
scale bar represents 100 μm.
B: Illustration of insulin loaded in situ forming depot.
C: SEM image of insulin nanoparticles. The scale bar represents 1000 nm.
D: Illustration of insulin loaded microsphere-hydrogel composite system.
Permissions:
A: Adapted with permission. Yu, W., Bien-Aime, S., Li, J., Zhang, L., McCormack, E.S.,
Goldberg, I.D., Narayan, P. and Uhrich, K.E. (2015). Injectable microspheres for
extended delivery of bioactive insulin and salicylic acid. Journal of Bioactive and
Compatible Polymers, 30(3), 340-346.
C: Adapted with open access permission. Xiao, Y., Wang, X., Wang, B., Liu, X., Xu, X.,
& Tang, R. (2017). Long-term effect of biomineralized insulin nanoparticles on type 2
diabetes treatment. Theranostics, 7(17), 4301.
D: Reprinted from Acta biomaterialia, 64, Zhao, F., Wu, D., Yao, D., Guo, R., Wang, W.,
Dong, A., Kong, D. and Zhang, J., An injectable particle-hydrogel hybrid system for
glucose-regulatory insulin delivery, 334-345, 2017, with permission from Elsevier.
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study demonstrated that microspheres prepared from 30 kD poly lactic acid could
maintain normoglycemia in diabetic SD rats for 5 days [99]. Coating with ethyl vinyl
acetate or wax further prolonged insulin release and maintained normoglycemia for 2
weeks [100]. Since then, numerous injectable microspheres prepared from biodegradable
polymers have been investigated for controlled release of insulin. Although numerous
biodegradable and biocompatible polymers of natural and synthetic origin were used to
produce microspheres for proteins and peptides, the use of polymers to develop
microsphere formulations for insulin has been mostly limited to poly(lactic-co-glycolic
acid) (PLGA) [105, 106] and polylactic acid (PLA) [107, 108]. Table 3-1 provides
examples of microsphere formulations used in preclinical studies for sustained delivery
of insulin.
An ideal microsphere should have high API encapsulation efficiency and provide
conformational stability and sustained release of the encapsulated protein along with
optimum particle size and size distribution for easy injectability and low initial burst
[101, 109]. The rate and extent of drug release from microspheres largely depend on all
of these factors which, in turn, depend on the composition and fabrication techniques of
microspheres. Insulin containing microspheres are usually prepared by water/oil/water
(w/o/w) double emulsion-solvent evaporation method and also, to a lesser extent,
variation of w/o/w method such as solid/oil/water (s/o/w) [110, 111] and solid/oil/oil
(s/o/o) [112]. Insulin microspheres are also prepared by spray drying process [113].
Because of its simple process, robust control on process parameters and inexpensive
instrumentation, w/o/w double emulsion-solvent evaporation method is most widely used
in this regard [109]. In this method, aqueous insulin is first dispersed in a polymer
containing organic solvent to form a w/o emulsion which is called primary emulsion. The
primary emulsion is then dispersed into large volume of water (which contains
emulsifier) to obtain w/o/w emulsion. In the final step, the organic solvent is evaporated
in reduced pressure. This method resulted in relatively small size of insulin containing
microspheres ranging from 3-5 μm up to less than 100 μm [108, 114, 115].
However, protein denaturation during microsphere preparation is a major concern
in traditional w/o/w method because removal of large volume of water during secondary
emulsification step often leads to protein denaturation at the water/solvent surface, low
loading efficiency and wide size distribution [116, 117]. To resolve this issue, zinc has
been used as insulin stabilizing agents during microsphere preparation. Manoharan et al.
demonstrated that the addition of zinc during the primary emulsification step (w/o)
increased the physical stability of insulin [118]. In this study, addition of zinc not only
stabilized insulin in the microspheres, it also increased the encapsulation efficiency and
decreased initial burst release. As a result, insulin was released from the microspheres for
more than two weeks [119]. Similarly, addition of cationic polyelectrolyte, poly(ethylene
glycol)-b-poly(L-histidine) diblock copolymer (PEG-polyHis), was also shown to
decrease the aggregation of insulin at the aqueous/organic interface during
microencapsulation process and preserved insulin stability during primary emulsification
step [120].
The stability of insulin can also be preserved following s/o/w fabrication method
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Table 3-1.
Examples of microsphere formulations used in preclinical studies for
sustained delivery of insulin
Fabrication
Techniques
s/o/w emulsionsolvent
evaporation
w/o/w double
emulsion-solvent
evaporation

Polymer,
Molecular
Weight
PLGA (50:50),
6600 Da

Size

Animal Model

Key Findings

Ref.

15–30
μm

STZ-induced
diabetic male
Wister rats
STZ-induced
diabetic male
Sprague-Dawley
rats
Alloxan-induced
New Zealand
White rabbits

low initial burst and
sustained insulin release
for 2 weeks.
Sustained insulin
release for more than 40
days.

[121]

Sustained insulin
release up to 40 days
and showed
biocompatibility in 12
weeks study.
Controlled release of
insulin for 35 days.

[122]

Multi-arm histidine
copolymer loaded
microspheres
maintained
normoglycemic effect
for 4 weeks.
Glucose lowering effect
maintained for 1 week.

[114]

Sustained insulin
release for 1 week.

[108]

Sustained insulin
release for 21 days.

[124]

Normoglycemia
maintained after
subcutaneous injection
in every 10 days.
Maintained
normoglycemia up to 60
days.
Normoglycemia
maintained from 7th day
to 10th day after
injection.
Maintained
normoglycemia for
about 16 days.

[125]

p(CPH/SA)
(40:60, 50:50),
24000 Da,
16000 Da
PLGA (50:50)

~ 40 μm

p(CPP:SA)
(50:50), 21000
Da

41.5 to
49.8 μm

w/o/w double
emulsion-solvent
evaporation

PLGA (85:15),
MW 5000075000 Da

14-15 μm

w/o/w double
emulsion-solvent
evaporation
w/o/w double
emulsion-solvent
evaporation

PLGA (50:50)
and PLA, MW
45000 Da
PLA, 21400
Da and
PEG, 2000 Da

36-37 μm

w/o/w double
emulsion-solvent
evaporation

PLGA (50:50),
MW 3800054000 Da

5.9±0.5
μm

s/o/w emulsionsolvent
evaporation

PLGA (50:50),
MW 5800 Da

Not
Available

Diabetes prone
BB/Wor//Tky rats

w/o/w double
emulsion-solvent
evaporation
s/o/w emulsionsolvent
evaporation

PCL, 72000
Da

37-52 μm

STZ-induced
male Wister rats

PLGA (50:50),
MW 6000 Da

0.3-0.5
μm

STZ-induce male
Wister rats

w/o/w double
emulsion-solvent
evaporation

PLGA (50:50),
MW 12000 Da

Not
available

STZ-induced
diabetic Kunming
mice

w/o/w double
emulsion- and
s/o/w emulsionsolvent
evaporation
w/o/w double
emulsion-solvent
evaporation

w/o/w:
55 μm
s/o/w: 20
μm

3-5 μm

STZ-induced
diabetic male
Sprague-Dawley
rats
STZ-induced
diabetic male
Sprague-Dawley
rats
Alloxan induced
diabetic female
Wister rats
STZ-induced
diabetic female
Sprague-Dawley
rats
STZ-induced
diabetic male
Wister rats
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[115]

[123]

[107]

[126]
[127]

[128]

a slight variation of traditional w/o/w method [129]. In this method, solid insulin particles
are dispersed in the polymer solution to form s/o emulsion which is then introduced into
large volume of aqueous solution that contains emulsifying agent. The addition of solid
protein particle reduces the conformational mobility of insulin which is often observed in
dissolved proteins and results in higher protein stability as well as higher encapsulation
efficiency [109]. For example, Bao et al. fabricated PLGA microspheres by s/o/w process
and insulin encapsulation was found to be more than 90% (w/w) with an insulin loading
efficiency of 15% (w/w) [111]. The system also showed significantly lower initial burst
compared to insulin containing microspheres prepared by w/o/w method.
Spray drying method is another method to prepare insulin loaded microspheres.
The main advantages of this method are easy process control and convenience in scale-up
[130, 131]. In this method, protein solution or emulsion (w/o or s/o) is atomized at an
elevated temperature to evaporate the organic solvent [109, 132]. The insulin containing
microspheres prepared by spray drying method demonstrated lower initial burst and
maintained its chemical and conformational stability [133]. Different excipients added
during spray drying process are also found to modulate microsphere properties. For
example, co-encapsulation of HPβCD with inuslin in PLGA microspheres slowed down
the insulin release rate and mainatined conformational stability of encapsulated and
released insulin [133]. Similarly, insulin encapsulated with phospholipids such as
glycerol monostearate and glycerol distearate in PLGA microsphere showed higher
encapsulation efficiency of about 90% [113].
As mentioned, the high initial burst is a major problem in microsphere-based
sustained release delivery systems because of uneven distribution of drug molecules and
its porous surface which allow easy diffusion of encapsulated drugs [134, 135]. This
problem is paramount especially for insulin where higher initial burst can cause severe
hypoglycemia resulting in life-threatening situation. To address this problem, double
walled PLGA microsphere was developed using water/oil/oil/water (w/o/o/w) emulsion
solvent evaporation technique and compared with microspheres prepared by conventionl
w/o/w method [106]. Double walled microspheres exhibited non-porous smooth surface,
smaller particle size and significant reduction in initial burst compared to microspheres
prepared in conventional way. The higher initial burst also depends on the nature of the
polymer. The hydrophilic characteristics of polymer also affect the initial burst and
overall release of insulin from the microspheres. For example, Presmanes et al.
demonstrated that acid terminated PLGA microspheres (more hydrophilic) showed higher
initial burst compared to ester terminated PLGA microspheres (which is less hydrophilic)
[124]. As a result, ester terminated PLGA microspheres maintained hypoglycemic effect
up to 4 weeks while acid terminated PLGA microspheres showed hypoglycemic effect
for less than two weeks. Molecular weight of the polymers is another important factor
affecting the size, encapsulation efficiency and drug release from the microsphere [136,
137]. High molecular weight PLGA microsphere (35813 Da) generated larger particle
size compared to low molecular weight PLGA microspheres (6065 Da) but insulin
encapsulation efficiency was found to be lower for high molecular weight microspheres
[138]. High MW PLGA microsphere also demonstrated lower initial burst of insulin
prolonged insulin release compared to low MW microspheres [138].
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Several microsphere based sustained release systems have been developed for
insulin which successfully demonstrated long-term normoglycemia ranging from days to
months in preclinical studies. Table 3-1 summarizes such preclinical studies in which
glucose lowering effect was observed for at least one week after injection of insulin
loaded microspheres. It shows that that most of the microsphere formulations used in
preclinical studies are prepared from poly lactic-co-glycolic acid. The molecular weight
of PLGA used in these studies ranged from 5000 Da to 75000 Da. These PLGA
microspheres maintained sustained insulin release for up to five weeks where higher
molecular weight microspheres showed longer release profile. The biocompatibility,
customizable mechanical and degradation properties, tunable drug release kinetics via
structural modification and most importantly, approval from FDA for parenteral
administration has made PLGA an attractive polymer for developing controlled release
parenteral formulations [139].
Therefore, PLGA based microspheres gained much attention and have been
subject to considerable research which led to the approval of several PLGA based
microsphere products in the last few years [140]. As a consequence, the first PLGA based
insulin microsphere formulation (AB101) has been approved for Phase І first in human
clinical trial as a once-weekly treatment for diabetes [141]. However, the formulation of
AB101 is different than formulations investigated in preclinical studies. Low molecular
weight (5 kD) PEG was first conjugated with B chain N-terminus of recombinant human
insulin to facilitate the dissolution of insulin in oil or water based solution during
emulsification step [142]. PEGylated insulin was then co-dissolved with PLGA in oil
phase and finally uniform microspheres are obtained via o/w emulsion technique [142].
AB101 is formulated in single step emulsification method whereas the microspheres
reported in preclinical studies (Table 4) were prepared in double emulsion method which
is associated with scale-up production difficulties [109]. In AB101, PEGylation of insulin
facilitates dissolution in oil phase which resulted in uniform distribution of insulin in the
microspheres leading to predicted release kinetics observed in preclinical studies. On the
other hand, the preclinical stage microspheres usually used human or bovine serum
insulin suspended in water phase during first emulsification step of microsphere
preparation which might lead to uneven distribution of insulin in the microspheres
causing burst release and unpredictable release kinetics. In this respect, future
development should consider use of long acting insulin analogues, PEGylated/lapidated
insulin or coencapsulation of cationic polymers to obtain microspheres with less initial
burst and more predictable long term release. Further investigations are also warranted to
address the inherent issues of microsphere based technology such as poor in vitro-in vivo
correlation, and scale-up production cost to take preclinical formulations into clinical
stage [143-145].
In situ Forming Depots
Injectable in situ forming depots are low viscosity injectable polymeric solution
or suspension which, upon injection, forms a semi-solid or solid polymeric matrix at the
injection site [146-148]. The solidification of polymer occurs via different mechanisms
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such as photo cross-linking [149, 150] or pH change [151, 152], temperature [153] and
solvent exchange [148, 154]. The drug entrapped in the polymeric matrix is released in a
sustained manner providing desired drug concentration in the systemic circulation for a
prolonged time. The polymers used in this case are usually biodegradable in nature which
undergo degradation over time and are eventually cleared from the body. In situ forming
depots were developed as an alternative controlled release system to overcome some of
the disadvantages of microspheres such as high fabrication cost, needle clogging, the
need of reconstitution, and migration after injection [143-145]. Among different types of
in situ forming depots, temperature-sensitive and phase-sensitive (solvent-exchange)
systems have been primarily reported for sustained release of insulin.
Thermosensitive In Situ Forming Depots
Thermosensitive in situ forming depots refer to polymeric solution which
undergoes solution to gel transition in response to the change in temperature. The
temperature at which the phase transition occurs is called critical gelation temperature.
Certain polymers are characterized by their lower critical gelation temperature (LCGT)
and upper critical gelation temperature (UCGT) [146]. At LCGT, the polymeric solutions
remain in solution state with lower viscosity but undergo gelation when the temperature
goes above LCGT. When the temperature again starts to approach UCGT, the gel
structure starts to rupture and is transformed into solution again. Polymers used to
develop thermosensitive in situ forming depots usually have their LCGT between room
and physiological temperature (37 ͦ C) and therefore, they are liquid in room temperature
and becomes solidified when injected into the body [155].
Various thermosensitive in situ forming depots have been designed as controlled
release carrier for insulin [101, 156]. The polymers used in this purpose are usually
thermosensitive block polymers which are either non-ionic co-polymers, cationic
polymers or less commonly polypeptides. Poloxamers, Poly (ethylene oxide)/poly
(propylene oxide)/poly (ethylene oxide) (PEO-PPO-PEO), are the first class of
thermosensitive block polymers approved by FDA. They are non-ionic in nature and
demonstrate sol-gel transition at body temperature at 15% (w/w) concentration and above
[146]. Due to their safety profile and good biocompatibility, poloxamer based in situ
forming gel systems have been explored for sustained insulin delivery [157, 158]. For
example, Yang et al. developed a sustained release delivery system using Poloxamer 407
(P407) and Poloxamer 188 (P188) [159]. To improve the mechanical properties,
hydroxypropyl methyl cellulose (HPMC) was added to the system. Insulin microcrystal
loaded Poloxamer/HPMC (P188:P407:HPMC = 9:20:3 %w/v) formulation demonstrated
hypoglycemic effect in diabetic SD rats for 3 days.
Attempts have also been made to deliver insulin with commercially available
thermosensitive non-ionic polymer such as ReGel® (PLGA-PEG-PLGA) which is on its
way towards FDA approval [160]. Kim et al. developed an injectable sustained release
formulation for insulin using ReGel® [161]. The formulation was composed of 23 wt%
copolymer solution with 0.2% zinc and 5.04 mg/ml insulin loaded formulation achieved
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sustained insulin release up to 15 days after a single subcutaneous injection in SpragueDawley (SD) rats. The same research group also studied the effect of this formulation on
Zucker Diabetic Fatty (ZDF) rat model [162]. In this study, the formulation was
developed with 6 mg/ml insulin in 23 wt% copolymer solution with 10 wt% zinc
carbonate. A single subcutaneous injection of this formulation maintained steady state
plasma levels of exogenous insulin for almost 2 weeks in type 2 diabetic ZDF rat model
and consequently, maintained normoglycemia during this period. Similarly. Tahami et al.
developed triblock copolymer with PLA and PEG by varying the PLA chain length and
insulin (at a dose of 90 U/kg body weight) containing PLA-PEG-PLA copolymer solution
(40% w/w) demonstrated continuous insulin release over a period of 3 months and
maintained blood glucose level of diabetic male Sprague–Dawley (SD) rats below 200
mg/dL [163]. Moreover, copolymer with higher PLA content showed lower insulin
release rate and longer duration of action because higher PLA content introduced more
hydrophobicity into the system. Although the delivery system released insulin for several
months, the conformational stability and secondary structure was partially reduced. To
increase the stability of insulin, Oak et al. used chitosan-zinc-insulin complex and loaded
into the previously mentioned PLA-PEG-PLA formulation [153]. Positively charged
chitosan was used to stabilize zinc-insulin hexamer in order to reduce the initial burst
(Figure 3-2). Chitosan-zinc-insulin complex significantly reduced the initial burst release
of insulin when compared with the release in the absence of chitosan and zinc [163]. The
delivery system composed of 30% (w/w) copolymer solution released insulin in
biologically active form and maintained normoglycemic level in diabetic SD rats for 70
days. Moreover, the delivery system did not produce any inflammation during the study
period and insulin, both released and extracted from the implant, was conformationally
stable.
Apart from PLGA and PLA based non-ionic block co-polymers, poly(ɛcaprolactone) (PCL) was also used as a component to synthesize temperature sensitive
block co-polymer for controlled delivery of insulin [164]. Huynh et al. developed 5
mg/ml insulin containing PCL-PEG-PCL (25 wt%) formulation which released insulin
for 4 days in diabetic SD rats after a single subcutaneous injection. However, the
formulation demonstrated high initial burst (>3500 mU/L) compared to free insulin
(<1000 mU/L) which was assumed to be caused by slow in vivo sol-gel transition of the
formulation after injection. This problem was resolved by adding cationic poly(β-amino
ester) which has been described later in this section.
The use of thermosensitive cationic polymers such as chitosan [165], poly(βamino ester) [166], poly(amidoamine) [167], poly(ethylene imine) [168], and poly(lysine)
[169] is another interesting strategy for the delivery of genes and protein molecules
because of their ability to bind anionic biomacromolecules. Insulin is negatively charged
in physiological pH and therefore, cationic polymers can provide stability in insulin when
mixed together. For example, Tahrir et al. used chitosan/β-glycerol phosphate (CS/βGp) co-polymer as a cationic delivery system for sustained insulin delivery [170]. The
system released 19% - 63% insulin in vitro for more than 6 days depending on the
amount of β-Gp in the system and the released insulin maintained its structural stability
during this time. A single subcutaneous injection of CS (2% w/v)/β-Gp (8% w/v)
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Figure 3-2. Chitosan-zinc-insulin loaded thermo-sensitive non-ionic in situ
forming depot
The thermo-responsive gel forms depot after subcutaneous injection. Degradation of
polymer as well as dissociation of insulin from chitosan-zinc-insulin complex prolongs
the duration of action of insulin.
Reprinted from Journal of controlled release, 163(2), Oak, M., & Singh, J., Chitosan–
zinc–insulin complex incorporated thermosensitive polymer for controlled delivery of
basal insulin in vivo, 145-153, 2012, with permission from Elsevier.
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formulation encapsulated with 0.01 mg/ml insulin into diabetic Balb/c mice demonstrated
glucose lowering effect for 5 days which was significantly longer than that of free insulin
solution which only lasted for only several hours. Cationic polymers can also be used to
synthesize dual-stimuli-responsive system such as both pH- and temperature-sensitive
system. For example, thermosensitive oligo(amidoamine/β-amino ester) (OAAAE) was
synthesized as a cationic copolymer for controlled insulin release [171]. At low pH such
as pH 6.6, the copolymer remained in its solution state in a wide range of temperature (0
– 70 ͦ C) but converted into gel in higher pH such as pH 7.4 (Figure 3-3). Subcutaneously
injected insulin (5 mg/ml) loaded OAAAE solution (20 wt%) maintained the insulin level
for 5 days in diabetic SD rats.
Similarly, Huynh et al. demonstrated that addition of positively charged poly(βamino ester) (PAE) can also significantly increase the release duration of insulin from
thermosensitive triblock copolymer PCL-PEG-PCL [164, 172]. To resolve the issue of
higher initial burst of PCL-PEG-PCL system mentioned earlier in this section, they
modified the triblock copolymer (PCL-PEG-PCL) by the addition of PAE into a
pentablock copolymer PAE-PCL-PEG-PCL-PAE. Addition of positively charged PAE
stabilized insulin by forming ionic bond with negatively charged insulin and also
conferred pH responsiveness into the system. At pH 3-4, the pentablock copolymer was
dissolved in DI water and remained in solution state but formed gel at physiological
temperature and pH upon subcutaneous injection (Figure 3-4). The hydrogel
significantly reduced the initial burst of insulin and10 mg/ml insulin loaded copolymer
solution (30 wt%) maintained a steady-state blood glucose level for more than 10 days
[172]. This is an interesting example of how temperature sensitive systems can be
tailored to obtain desired release profile.
Thermoresponsive sustained release systems has also been developed with
polypeptides. One such system was reported by Jeong et al. where synthesized poly
(ethylene glycol)-block-poly(alanine-co-phenyl alanine) (PEG-PAF) aqueous solution
showed solution to gel transition at 37 °C in a few seconds at a concentration as low as 37 wt% [173]. Insulin was loaded to 4 wt% PEG-PAF aqueous solution at a dose of 13.8
mg/kg/rat. A single injection of 0.5 ml formulation showed a glucose lowering effect
over 18 days in diabetic rats.
Phase Inversion Based In Situ Forming Depots
Phase inversion based in situ forming depots are prepared by dissolving
biodegradable and biocompatible polymer in a water-miscible and biocompatible organic
solvent and the drug is dissolved or suspended in the polymeric solution [147]. Upon
injection, the organic solvent is diffused out and the polymer precipitates forming a depot
in the subcutaneous space (Figure 3-5). The drug remains in the depot and is released in
a sustained manner via diffusion and erosion of the polymeric depot. Dunn et al. first
proposed this system in 1990 by incorporating biodegradable polyesters such as PLA and
PLGA in water miscible organic solvents such as N-methyl-2-pyrrolidone (NMP) and
dimethyl sulfoxide [137, 154]. Since then, different phase inversion based in situ forming
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Figure 3-3. Insulin loaded thermo-sensitive cationic in situ forming depot
Positively charged oligo(amidoamine/β-amino ester) oligomers undergo gelation via
hydrogel bonds and hydrophobic interaction and entrap negatively charged insulin in
physiological pH and temperature after subcutaneous injection. Degradation of the
oligomer matrix slowly release insulin from the polymer depot at the injection site.
Reprinted with permission. Nguyen, M. K., Huynh, C. T., Gao, G. H., Kim, J. H., Chae,
S. Y., Lee, K. C., & Lee, D. S. (2011). Biodegradable oligo (amidoamine/β-amino ester)
hydrogels for controlled insulin delivery. Soft Matter, 7(6), 2994-3001.
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Figure 3-4. Thermo-sensitive pentablock co-polymer based cationic in situ
forming depot
A) PAE-PCL-PEG-PCL-PAE (complex gel) demonstrated no initial burst and maintains
steady state plasma insulin level for two weeks. B) Mechanism of insulin release from
complex gel: (a) the polymer solution at low temperature and pH forms ionic complex
with insulin, (b) gel formation at physiological pH and temperature results, (c) slow
degradation of polymer releases insulin in sustained manner.
Adapted from Biomaterials, 29(16), Huynh, D.P., Nguyen, M.K., Pi, B.S., Kim, M.S.,
Chae, S.Y., Lee, K.C., Kim, B.S., Kim, S.W. and Lee, D.S., Functionalized injectable
hydrogels for controlled insulin delivery, 2527-2534, 2008, with permission from
Elsevier.

30

Figure 3-5. Phase inversion based in situ forming depot
Phase-sensitive PLGA based in situ forming depot precipitates and forms solidified
PLGA matrix after injection. Drug is released in a sustained manner from the matrix via
diffusion and matrix erosion.
Reprinted from Journal of controlled release, 172(1), Parent, M., Nouvel, C., Koerber,
M., Sapin, A., Maincent, P., & Boudier, A., PLGA in situ implants formed by phase
inversion: Critical physicochemical parameters to modulate drug release, 292-304, 2013,
with permission from Elsevier.
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systems have been developed and evaluated for their ability to provide controlled release
of various proteins and peptides [174, 175]. Insulin has also been used as a drug in phase
inversion based in situ forming depots for longer release, although there are very few
reports available which are mostly based on PLA and PLGA.
Kang et al. used PLA as a polymer to develop a phase inversion based system for
controlled delivery of insulin [176]. The delivery system was prepared by dissolving PLA
(15 or 30% w/v) in benzyl benzoate (BB) and benzyl alcohol (BA) solvent mixture and
insulin was mixed at a level of 4% (w/v). The systems released 15-75% insulin for more
than 2 months in vitro. A change in insulin release was observed when hydrophilic
(benzyl alcohol) and hydrophobic (benzyl benzoate) solvent ratio and polymer
concentration were changed. Histopathological study showed that the system was nontoxic after 12 weeks of implantation. Although the system showed promising sustained
release data in in vitro study, the system’s performance is inconclusive due to the lack of
in vivo data. However, Dhawan et al. performed a similar study with PLGA containing
phase inversion based system by varying the solvent ratio of benzyl benzoate and benzyl
alcohol [177]. Several formulations were developed by changing the PLGA, BB and BA
concentration and in vivo glucose lowering effect was tested on diabetic male LACA
mice. The formulation composed of 2 mg/g insulin, 30 wt% PLGA and 20% (w/v) BB
and 80% (w/v) BA showed glucose lowering effect for 16 days after a single injection
compared to routine once-a-day insulin administration. SDS-PAGE and CD spectroscopy
revealed that insulin released from the formulation in in vitro study was conformationally
stable.
In a similar study, Anand et al. developed another PLGA based phase inversion
based systems composed of triethyl citrate (TEC) and acetyltriethyl citrate (ATEC) as
plasticizer [178]. The formulations were composed 4% (w/w) insulin glargine and 5%
(w/w) PLGA dissolved in ATEC and TEC mixture with or without zinc sulfate (0.10.5%). The PLGA gel formulations prepared with insulin glargine particles maintained
normal blood glucose level for 10 days after a single subcutaneous injection but showed a
sudden blood glucose drop in diabetic ZDF rats possibly due to high initial burst.
Addition of zinc sulfate slowed down the blood glucose drop in a concentration
dependent manner (Figure 3-6). The use of long-acting insulin analogue glargine and
addition of zinc combinedly promoted hexamer formation leading to slower insulin
release and steady blood glucose drop in this study. As a result, sustained insulin release
was achieved for more than one week even with low concentration of polymer solution
(5% w/w) which provided easy injectability.
Glucose Responsive In Situ Forming Depots
Apart from thermo-sensitive and phase inversion based in situ forming depots,
one new kind of gel based system is glucose responsive polymeric gels developed by coencapsulation of insulin with glucose responsive enzyme such as glucose oxidase. High
glucose concentration triggers glucose oxidase mediated conversion of glucose into
gluconic acid which causes local pH drop. Consequently, the polymeric matrix is swelled
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Figure 3-6. Comparison of blood glucose lowering effect of PLGA phase inversion
based in situ forming depot with various zinc sulfate concentrations in ZDF rats
Reprinted by permission from The American Association of Pharmaceutical Scientists:
Springer Nature, AAPS PharmSciTech, Controlled release of modified insulin glargine
from novel biodegradable injectable gels Anand, O., Almoazen, H., Mehrotra, N.,
Johnson, J. and Shukla, A., 2012.
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and degraded causing insulin release which is stopped when blood glucose returns to
normal level. One example of such system has been found so far which was developed by
Fu et al. and utilized a pH sensitive peptide hydrogel called RATEA-16 [179]. RATEA16 hydrogel undergoes self-assembly in physiological pH but is disassembled in low
environmental pH. After injection, insulin and glucose oxidase loaded hydrogel is selfassembled at physiological pH. In hyperglycemic condition, the conversion of glucose
into glucuronic acid decreased the local pH resulting in the disassembly of hydrogel
resulting in slow insulin release. The system regulated the blood glucose levels of STZinduced diabetic rats effectively for up to 8 days.
As discussed, thermosensitive systems are mostly composed of block copolymers
with hydrophobic and hydrophilic content whereas phase-sensitive systems are developed
with polymers which are soluble in organic solvents such as NMP and DMSO etc.
Thermo-sensitive systems can be tuned to vary the rate of insulin release by altering
hydrophilic/hydrophobic content of the copolymer [156] as well as by varying the
properties of the copolymer components [164, 172]. Similarly, phase inversion based in
situ forming depots can be developed with tunable release properties by varying the
polymer concentration, solvent composition, and by the addition of additives [180, 181].
Regardless of the system, polymer concentration of 15-30% has been found to
demonstrate sustained insulin release for at least one week while maintaining the ease of
injectability. However, phase inversion based systems suffer from issues inherent to this
system such as local irritation at the injection site due to high amount of organic solvent,
polymer instability in the solvent system and denaturation of protein drugs in the
presence of organic solvents [147]. In this respect, thermo-sensitive systems are usually
preferred for the development of in situ forming depots for sustained insulin release
especially due to the absence of organic solvent. However, high initial burst,
unpredictable release kinetics, poor in vitro-in vivo correlation, variation in implant size,
incomplete implant formation, protein instability due to protein-polymer interaction as
well as increase in local pH due to polymer degradation remain issues in both systems
[146, 147, 181-184]. Like microspheres, high initial burst during the first few hours after
injection is also crucial as it might cause severe hypoglycemia [185, 186]. However,
addition of zinc, cationic polymers and use of long-acting insulin analogues have been
found to improve the burst release [153, 178]. In addition to this, development of robust
in vitro release method that can predict the in vivo release profile from the in situ implant
can resolve the issues related to poor in vitro-in vivo correlation and accelerate
formulation screening. But unpredictable release kinetics still remains an unresolved
problem in this respect even after employing several novel imaging techniques to
evaluate implant formation and subsequent drug release kinetics [183, 187].
Nanoparticles
Nanoparticles are carriers with a size range of 10-1000 nm [101]. The emergence
of nanoparticle-based drug delivery systems has revolutionized the area of protein and
peptide drug delivery. Owing to their advantage of transporting drugs across various
biological barriers, improved bioavailability and target specific delivery, nanoparticle-
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based drug delivery systems has been widely studied for protein and peptide delivery in
the past decade [188, 189].
Nanoparticle-based delivery systems have been mainly investigated for efficient
oral delivery of insulin because of their smaller size, enhanced pharmacokinetic property
and protective nature towards encapsulated insulin [190-192]. But there are few reports
on nanoparticles as a sustained release carrier for insulin delivery. One such study
investigated sustained release behavior of insulin loaded positively charged
dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) co-polymer
based nanoparticles with a size range of 122.7 nm to 1762.4 nm [193]. The positively
charged copolymer formed nanoparticles with negatively charged insulin via ion
mediated nanoparticle aggregation. After subcutaneous injection, the aqueous suspension
of nanoparticle aggregates formed an in situ depot which released insulin in vitro for
about two weeks. The release profile showed triphasic insulin release starting from initial
burst, then pore diffusion and finally insulin release from swollen matrix which is typical
in particle based sustained release systems [194]. However, no in vivo study of this
system was reported.
Nanoparticles prepared from commonly used polymers have been investigated
and sustained in vivo insulin release has been achieved for several days. Abdelkader et al.
developed PLGA nanoparticles with size ranging from 200-300 nm and these
nanoparticles released more than 60% of insulin for more than 6 days in in vitro release
study [195]. Subcutaneous injection of optimized nanoparticle formulation demonstrated
significant glucose lowering effect in STZ-induced male SD diabetic rats throughout the
six days study compared to free human insulin and insulin-zinc suspension. After 6 days,
the % basal glucose level was 86.8% for nanoparticle formulations whereas % basal
glucose level increased to approximately 106% for both free human insulin and insulinzinc suspension. In another study, Haggag et al. reported insulin loaded PLGA-PEG
block copolymer based nanoparticles via a slight modification of traditional double
emulsion-solvent evaporation method (Figure 3-7) [196]. Increase in PEG content was
found to increase the encapsulation efficiency of insulin which might be due to the
hydrophilicity of PEG that promotes higher insulin attachment on nanoparticle surface.
The nanoparticles were negatively charged with a size range of 200-400 nm and the size
was increased with the increase in PLGA content. Also, Subcutaneous injection of insulin
loaded nanoparticles, at 25 U/kg body weight dose and 10% PEG content, demonstrated
sustained hypoglycemic effect for 6 days in STZ-induced diabetic Swiss TO mice.
Nanoparticle based sustained insulin release has been studied with less commonly
used biopolymers such as poly(hydroxybutyrate-co-hydroxyhexanoate) (PHBHHx)
copolymer [197]. In this study, insulin was first complexed with phospholipid (soybean
lecithin) to increase the lipohilicity of insulin which in turn increased the encapsulation
efficiency in PHBHHX nanoparticles. The mean particle size of the nanoparticles was
186.2 nm and the nanoparticles showed very slow in vitro insulin release given that only
20% of insulin was released within the first 31 days. However, the nanoparticles, at a
dose of 4 IU/kg, maintained hypoglycemic effect in STZ induced diabetic rats for more
than 3 days after single subcutaneous injection. The blood glucose level remained less
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Figure 3-7. Sustained release PEG-PLGA nanoparticles
PEG-PLGA block copolymer based insulin loaded nanoparticles synthesized via double
emulsion-solvent evaporation method. Insulin maintained its conformational stability in
nanoparticles demonstrated in insulin sensitivity study in type 2 diabetic mice as well as
showed normoglycemia for 6 days.
Reprinted from International journal of pharmaceutics, 499(1-2), Haggag, Y., AbdelWahab, Y., Ojo, O., Osman, M., El-Gizawy, S., El-Tanani, M., Faheem, A. and
McCarron, P., Preparation and in vivo evaluation of insulin-loaded biodegradable
nanoparticles prepared from diblock copolymers of PLGA and PEG, 236-246, 2016, with
permission from Elsevier.
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than 70% of initial level during this time.
Enzymes have been incorporated into the nanoparticle to achieve enzyme
mediated degradation of nanoparticles to release insulin in sustained manner (Figure
3-8). Chou et al. developed insulin loaded self-assembled nanoparticles of 40 nm size
with carboxymethyl-hexanoyl chitosan and co-encapsulated with lysozyme to achieve
enzyme mediated degradation of nanoparticles [198]. 10 μg/ml lysozyme containing
insulin loaded chitosan nanoparticles were injected subcutaneously in STZ-induced
diabetic male BLTW:CD1 (ICR) mice. The nanoparticles were degraded by lysozyme
and as a result, insulin was released slowly from the system. The nanoparticles with
lysozyme maintained normoglycemia for 10 days with a stable blood glucose level
whereas the nanoparticles without lysozyme showed normoglycemia for less than 5 days.
Glucose-responsive nanoparticle has been emerged as a newer strategy in the last
few years for sustained delivery of insulin [28]. As we know that blood glucose
concentration is the central stimuli for native insulin secretion from pancreas, glucose
responsive nanoparticles can release insulin in response to the glucose concentration i.e.
insulin is released from the system when the glucose concentration rises and is stopped
when glucose level returns to normal. Gu et al. developed glucose responsive dextran
nanoparticles with a size range of 290-340 nm by encapsulating insulin and glucoseresponsive enzymes such as glucose oxidase and catalase [199]. The dextran
nanoparticles were then coated with either positively charged chitosan or negatively
charged alginate which, when mixed together, formed a nano network (Figure 3-9). In
hyperglycemic condition, glucose oxidase mediated conversion of glucose into gluconic
acid increased the pH of the environment surrounding nanoparticles. As a result, the nano
network underwent pH mediated degradation and released insulin slowly. The insulin
release was halted when the glucose concentration returned to normal. A single
subcutaneous injection of these nanoparticles maintained normoglycemia for up to 10
days in STZ-induced diabetic male C57B6 mice. Conversely, insulin loaded nano
network in the absence of glucose-specific enzyme maintained blood glucose level within
the normal range for only 2 days.
Xu et al. developed another intelligent glucose-responsive nano system
mesoporous silica nanoparticles [200]. Instead of encapsulating glucose specific enzymes
with insulin, the porous surface of the nanoparticles was covered with a layer-by-layer
coating of enzymes (glucose oxidase and catalase) and polyethyleneimine (PEI) (Figure
3-10). When glucose level is more than 7 mM, the conversion of glucose into gluconic
acid increased the surrounding pH. The increase in pH caused protonation of PEI which
resulted in repulsion and subsequent loosening of the PEI layers. Hence, insulin was
released through the pores of the nanoparticles. In normoglycemic condition, the PEI
layer maintained its integrity and prevented insulin release. Upon single subcutaneous
injection, the nanoparticles decreased the blood glucose level and maintained
normoglycemiafor more than 3 days. The design of these nanoparticles allows tunable
insulin release by adjusting the amount of PEI in the nanoparticles.
Glucose responsive moiety such phenylboronic acid has been incorporated as a
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Figure 3-8. Enzyme loaded sustained release nanoparticles
Carboxymethyl-hexanoyl chitosan nanoparticles maintain normoglycemia via sustained
insulin release mediated by lysozyme-controlled degradation of nanoparticles.
Reprinted from Journal of controlled release, 224, Chou, H. S., Larsson, M., Hsiao, M.
H., Chen, Y. C., Röding, M., Nydén, M., & Liu, D. M., Injectable insulin-lysozymeloaded nanogels with enzymatically-controlled degradation and release for basal insulin
treatment: In vitro characterization and in vivo observation, 33-42, 2016, with permission
from Elsevier.
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Figure 3-9. Sustained release of insulin from nano-network
(a) Formation of oppositely charged acid sensitive dextran nanoparticles encapsulating
insulin, glucose oxidase and catalase, (b) acid sensitive acetal-modified dextran, (c)
Sustained insulin release via pH mediated degradation of nano network caused by
glucose oxidase mediated glucose to gluconic acid conversion, (d) treatment of type 1
diabetic mice with glucose-responsive nanoparticles to maintain normoglycemia.
Reprinted with permission from Gu, Z., Aimetti, A.A., Wang, Q., Dang, T.T., Zhang, Y.,
Veiseh, O., Cheng, H., Langer, R.S. and Anderson, D.G. (2013). Injectable nano-network
for glucose-mediated insulin delivery. ACS nano, 7(5), 4194-4201. 2013 American
Chemical Society.
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Figure 3-10. Glucose responsive enzyme coated nanoparticles
Layer-by-layer coating of insulin containing mesoporous silica nanoparticle surface with
glucose-specific enzyme and PEI. The nanoparticles release insulin in a sustained manner
in response to high glucose concentration by enzyme mediated increase in local pH.
Reprinted with permission from Xu, C., Lei, C., Huang, L., Zhang, J., Zhang, H., Song,
H., Yu, M., Wu, Y., Chen, C. and Yu, C. (2017). Glucose-responsive nanosystem
mimicking the physiological insulin secretion via an enzyme–polymer layer-by-layer
coating strategy. Chemistry of Materials, 29(18), 7725-7732. 2017 American Chemical
Society.
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component of block copolymer to achieve glucose responsive sustained insulin release
[201]. For example, poly(d-gluconamidoethyl-methacrylate-block-3acrylamidophenylboronic-acid) (p(AAPBA-b-GAMA)) amphiphilic block glycopolymer
has been synthesized to develop self-assembled nanoparticles [202]. The self-assembly
occurred via cross-linking between diol groups of pAAPBA and pGAMA blocks. The
nanoparticles released up to 50% of encapsulated insulin for 48 days in in vitro release
study in conformationally stable form, although in vivo sustained release property of
these nanoparticles is yet to be explored [203, 204].
Nanoparticle based drug delivery possess several advantages such as targeted
delivery, superior penetration ability through biological barriers, prolonged circulation
time, enhanced permeation and retention ability and therefore, have been investigated for
their potential in different therapeutic areas. But studies regarding the use of
nanoparticles for sustained delivery of insulin is sparse and mostly limited to in vitro
studies. Furthermore, nanoparticle based sustained release systems, in general,
demonstrate several issues similar to microspheres such as variation between in vitro and
in vivo drug release profile, migration from the injection site and stability issues during
the nanoparticle synthesis process. Moreover, owing to their smaller size compared to
microspheres, nanoparticles often show lack of efficient renal clearance after drug release
and long-term safety concerns [205]. Although some studies reported sustained insulin
release for several days (maximum 10 days) using different nano systems, the breadth of
publications in this area is very limited to evaluate the potential of nanoparticles for longacting insulin therapy.
Composite Systems
Particle based sustained release systems such as microspheres and nanoparticles
have demonstrated sustained insulin release and maintained normoglycemia for
prolonged duration [108, 115, 153, 176, 196, 198, 206]. However, both microsphere- and
nanoparticle-based delivery systems possess some inherent disadvantages such as high
initial burst, migration from injection site and occasionally, stability issues during
encapsulation [134, 137, 205]. Composite systems such as particle-gel or particle-particle
hybrid systems have been investigated in several studies to overcome these issues. Zhao
et al. recently developed one composite system with phenylboronic acid (PBA) modified
PLGA microspheres loaded in dopamine modified hyaluronic acid hydrogel (DOP-HA)
[207]. At a low glucose level, PBA crosslinked with dopamine to form hyaluronic acid
layer around microspheres which acted as a diffusion barrier for insulin encapsulated in
microsphere (Figure 3-11). At a high glucose level, PBA-DOP crosslinking is disrupted,
and the hyaluronic acid layer detached from the microsphere resulting in insulin release
through pores. After subcutaneous injection, the insulin loaded microsphere-gel
composite system achieved normoglycemia for two weeks in STZ induced diabetic mice.
The advantage of this system is that it involves simple mixing and self-assembly of the
formulation components which can facilitate scaling up of this system for clinical
translation.
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Figure 3-11. Microsphere-gel based composite system
A: Microsphere-gel (MP-gel) composite system composed of phenylboronic acid (PBA)
modified poly(lactic-co-glycolic acid) (PLGA) microspheres coated with dopamine
(DOP) modified hyaluronic acid (HA) layer. At low glucose level, the DOP-HA layer is
densely packed on the microsphere surface which prevents insulin release.
B: At high glucose level, the DOP-HA layer is detached from the microsphere surface
causing sustained insulin release compared to PBS, MP-gel without insulin, free insulin
solution resulted prolonged normoglycemia.
Adapted from Acta biomaterialia, 64, Zhao, F., Wu, D., Yao, D., Guo, R., Wang, W.,
Dong, A., Kong, D. and Zhang, J., An injectable particle-hydrogel hybrid system for
glucose-regulatory insulin delivery, 334-345, 2017, with permission from Elsevier.
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Similar to microsphere embedded hydrogel system, Liu et al. developed a
controlled release system for insulin with PLGA nanoparticle embedded within PVA
hydrogel via physical cross-linking [208]. Insulin loaded PLGA nanoparticles with a
mean size of 615 nm were prepared by traditional double emulsion-solvent evaporation
technique and dispersed in 5% w/v PVA solution. The delivery system released insulin in
a sustained manner and maintained normal blood glucose level for 24 hours in diabetic
mice after one intraperitoneal injection. Although the delivery system maintained
normoglycemia similar to long acting insulin analogues, the intraperitoneal route is a
significant concern because of its invasive nature compared to traditional subcutaneous
route. In a previous study mentioned in section 4.3, Peng et al. demonstrated that insulinphospholipid complex loaded PHBHHx nanoparticles maintained therapeutic effect of
insulin in diabetic rats for more than 3 days [197]. In a follow-up study, the same group
loaded these nanoparticles in thermosensitive chitosan/β-glycerophosphate injectable
hydrogel to achieve longer action-time profile of insulin [209]. The glucose lowering
effect of this composite system lasted for more than 5 days in diabetic SD rats following
single subcutaneous injection (Figure 3-12). This is an excellent example of modifying
existing sustained release system to achieve longer release profile that can be applied to
other particle based sustained release systems as well.
Another novel strategy in this regard is the development of nanoparticle
embedded microsphere based systems [210]. These nanoparticle-in-microsphere systems
showed longer drug release profile compared to nanoparticle or microsphere alone [211].
Hasan et al. developed insulin loaded PCL nanoparticles encapsulated in PLGA
microsphere [212]. PCL nanoparticles (390 ± 17 nm) were prepared by w/o/w doubleemulsion solvent evaporation method and then encapsulated in PLGA microspheres by
w/o/w method. The size of the composite microspheres was 111 ± 4 μm and it released
insulin for about 4 days after single subcutaneous injection into STZ-induced diabetic
rats. Although these preclinical in vivo studies demonstrate that particle-particle or
particle-gel based composite systems can provide sustained release of insulin, there are
actually very few studies to assess the overall feasibility of composite systems in this
respect.
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Figure 3-12. Nanoparticle-gel based composite system
Representation of nanoparticle loaded hydrogel based composite system. Insulin
containing PHBHHx nanoparticle loaded in thermosensitive chitosan/β-glycerophosphate
injectable hydrogel retarded insulin release from nanoparticles and maintained
normoglycemia for 5 days.
Reprinted from Acta biomaterialia, 9(2), Author(s), Peng, Q., Sun, X., Gong, T., Wu, C.
Y., Zhang, T., Tan, J., & Zhang, Z. R., 5063-5069, 2013, with permission from Elsevier.

44

CHAPTER 4.

INJECTABLE INSULINS IN CLINICAL TRIALS

Different injectable delivery systems such as microspheres, in situ forming
depots, nanoparticles and composite systems have been explored for their potential to
achieve ultra-long action of insulin. Although most of them have been limited to
preclinical studies, a number of new candidates based on these delivery concepts are
advancing towards clinical trials. In fact, four such candidates are currently in early stage
clinical development which offer the hope of once-weekly insulin treatment in the near
future (Table 4-1). Different delivery methods have been exploited to develop these
candidates such as PEGylation, antibody or polypeptide conjugation and delivery via
microsphere to achieve longer action-time profile. The following section discusses the
design strategies and clinical status of these once-weekly insulin candidates.
AB101
AntraBio’s AB101 combines the concept of PEGylation and microsphere-based
delivery system. As mentioned in section 3.1, it was developed by the attachment of 5 kD
linear polyethylene glycol (PEG) polymer with ThrB30 side-chain of native human
insulin followed by encapsulation of the in PLGA microsphere [213]. Insulin is released
from the microsphere in a sustained manner by diffusion and degradation of PLGA.
Single dose subcutaneous administration of AB101 demonstrated slow onset, sustained
insulin release and corresponding glucose reductions for 1 weeks in diabetic rats and
dogs [214]. AntraBio Inc. recently announced first-in-human clinical trials of AB101 as a
once weekly sustained release insulin delivery system [141]. This is the only
microsphere-based insulin formulation which is in Phase І clinical trial.
HM12460A (LAPSInsulin) and HM12470 (LAPSInsulin 115)
Hanmi Pharmaceuticals developed novel insulin analogue called LAPSInsulin and
LAPS
Insulin 115 by conjugating regular insulin or insulin 115 with constant region of a
human immunoglobulin Fc fragment (LAPS carrier) through a 3.4 kD PEG linker [215].
Both of the products deminstrated sustained insulin release and prolonged glucose
lowering efficacy for more than a week with a reduction in weight gain in preclinical
studies with pigs, SD rats and db/db mice where HM12470 demonstrated better efficacy
than HM12460 [216, 217]. Both products are undergoing phase І clinical trial.
PE0139 (Insumera)
PhaseBio Pharmaceuticals has developed PE0139 as a once weekly injection for
the treatment of diabetes. In PE0139, native insulin molecule has been genetically fused
to elastin-like polypeptide (ELP) biopolymer at AspA21 position. PE0139 is expressed in
Escherichia Coli as a genetic fusion of ELP1-120 biopolymer and proinsulin. The
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Table 4-1.

Injectable sustained release systems for insulin under clinical trials

Name

Company

Structural
Design

Dosing
Frequency

NN1436 (LAI287)

Novo Nordisk

Not disclosed

AB101

AntriaBio Inc.

Once
weekly
Once
weekly

PEGylated
insulin
encapsulated in
PLGA
microspheres
HM12460A/HM12470) Hanmi
Fc–insulin
(LAPSInsulin/LAPSInsulin Pharmaceuticals conjugate
115)
PE0139 (Insumera)
PhaseBio
Elastin-like
polypeptide
fusion

Clinical
Trial
Status
Phase I
Phase I

Once
weekly

Phase I

Once
weekly

Phase
IIa

Sources: Zaykov, A. N., Mayer, J. P., & DiMarchi, R. D. (2016). Pursuit of a perfect
insulin. Nature Reviews Drug Discovery, 15(6), 425. Cheung, K. K. T., & Senior, P. A.
(2015). Novel and emerging insulin preparations for type 2 diabetes. Canadian journal of
diabetes, 39, S160-S166.
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proinsulin is then converted into insulin during the downstream processing [218, 219]. In
phase І clinical study, PE0139 demonstrated prolonged insulin release along with low
peak-to-trough ratio that would enable once-weekly dosing regimen [220]. The molecule
is now in Phase 2a clinical trial [221].
NN1436 (LAI287)
LAI287 also known as insulin-287 is a once weekly insulin analogue developed
by Novo Nordisk. LAI287 has been reported as a lipidated insulin analogue but the
detailed design of the analogues is undisclosed [213]. The phase І clinical trials have
been completed and the company expects to initiate the Phase ІІ clinical trials very soon
[222].
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CHAPTER 5.

CONCLUSION AND PERSPECTIVE

Since its discovery, insulin has been the mainstay of treatment for diabetes
mellitus for nearly 100 years. However, achieving normoglycemia for a prolonged time
while avoiding the risk of hypoglycemia as well as achieving patient compliance and
medication adherence through less frequent injection have always been major challenges
with insulin therapy. The longest acting insulin available in the market requires oncedaily injection to maintain desired glucose lowering effect which is still inconvenient for
patients and therefore, presents significant risk of medication non-adherence. Thus,
several strategies have been explored over the past few decades to prolong the actiontime profile of insulin to obviate the need of once-daily injection. These strategies have
been divided into two categories: altering amino acid sequences and/or chemical
conjugation with polymers to develop long acting insulin analogues and developing
sustained release delivery systems such as microspheres, in situ forming depots,
nanoparticles and composite systems. The sustained release systems have been
successfully demonstrated to release insulin for days to weeks in preclinical studies.
However, one major drawback of these preclinical studies is that the system’s
performance is only measured by measuring glucose lowering effect which is an indicator
of short-term glycemic control. These preclinical reports lack HbA1c reduction study
which is more relevant for measuring the performance of long-lasting insulin therapy.
Also, there are several other limitations such as lack of compendial in vitro release
method, insulin instability, loss of biological activity, poor in vitro-in vivo correlation,
higher initial burst, migration of the particle based systems from the injection site,
manufacturing costs, need for reconstitution and sometimes unpredictable in vivo release
from the delivery systems, which need to be addressed for successful translation of these
preclinical strategies into clinical setting. However, advancements in recombinant DNA
technology and protein chemistry coupled with the advances in material and formulation
sciences as well as microfabrication techniques have been able to address some of these
issues and enabled several once-weekly candidates to progress to the clinical trials.
Future development efforts should focus on novel macromolecular modifications of
insulin such as peptide and antibody conjugation as well as microspheres and in situ
forming depots considering significant attention of FDA on the development of these
complex sustained release delivery systems. In addition, glucose responsive systems
should also be considered as focal point of research and developmental efforts as next
generation injectable sustained release system for insulin.
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